Johnson & Johnson has reached an agreement with the Stop TB Partnership that will allow generic bedaquiline versions of the firm’s Sirturo brand to be supplied in LMICs where patents remain in effect – but critics say the deal does not go far enough.
Under a deal that has just been struck by Johnson & Johnson and the Stop TB Partnership, generic versions of J&J’s Sirturo (bedaquiline) tuberculosis treatment will be able to be supplied in low-and middle-income countries despite existing intellectual property for the brand.
Announcing the agreement – which came “following lengthy negotiations” – the Stop TB Partnership, which is a United Nations hosted...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
